RedHill Biopharma Ltd. (RDHL)
NASDAQ: RDHL · Real-Time Price · USD
2.240
-0.070 (-3.03%)
At close: Apr 23, 2025, 4:00 PM
2.200
-0.040 (-1.79%)
Pre-market: Apr 24, 2025, 4:38 AM EDT
RedHill Biopharma Revenue
In the year 2024, RedHill Biopharma had annual revenue of $8.04M with 23.17% growth. RedHill Biopharma had revenue of $5.47M in the half year ending December 31, 2024, a decrease of -81.97%.
Revenue (ttm)
$8.04M
Revenue Growth
+23.17%
P/S Ratio
0.34
Revenue / Employee
$229,800
Employees
35
Market Cap
3.96M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 8.04M | 1.51M | 23.17% |
Dec 31, 2023 | 6.53M | -55.27M | -89.43% |
Dec 31, 2022 | 61.80M | -23.96M | -27.94% |
Dec 31, 2021 | 85.76M | 21.40M | 33.25% |
Dec 31, 2020 | 64.36M | 58.07M | 923.03% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
RDHL News
- 6 days ago - RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency - PRNewsWire
- 8 days ago - RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption - PRNewsWire
- 13 days ago - RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights - PRNewsWire
- 5 weeks ago - RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation - PRNewsWire
- 6 weeks ago - RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results - PRNewsWire
- 7 weeks ago - RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum - PRNewsWire
- 2 months ago - RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties - PRNewsWire
- 2 months ago - RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer - PRNewsWire